23andMe, Mirador enter strategic research collaboration

23andMe (ME) and Mirador Therapeutics announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360 development engine to enable target validation and precision medicine. “Mirador is a pioneer in I&I precision medicine, and our collaboration harnesses the power of 23andMe’s data and research platform to identify new targets and develop promising new drugs,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We hope this can ultimately help the millions of patients living with a range of I&I diseases who urgently need treatment options.”